Studienliste - Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie - Inselspital Kontakt

61 Aktive Studien der Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie

FACHGEBIETE

andere

Ordner-Nr.

  • SENS: A structured early palliative care intervention for patients with advanced cancer – a randomized controlled trial with a nested qualitative study SENSTrial)

    Kurzprotokoll
 Studienleiter:Prof. Dr. med. Steffen Eychmüller
 Co-Investigator:Frau Monica Fliedner
 Study-Nurse:Frau Renata Bünter


Status: aktiv seit 01.12.2013

 

Ordner-Nr.

  • PALL-DEC: Clinical decision-making in palliative situations: The role and prerequisites of patients’ mental representation.
 Studienleiter:Prof. Dr. Jürg Bernhard
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio


Status: aktiv seit 20.10.2014

 

Ordner-Nr. 2016-00520

  • Genetic characterization and enumeration of single, circulating tumour cells isolated from blood of renal cell carcinoma patients.
 Studienleiter:Dr. med. Julian Schardt
Hinweis: Studie wird nicht durch die KFE der UKMO betreut.


Status: aktiv seit 16.06.2016

 

Ordner-Nr. 2016-00008

  • DOSIS Studie: Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) versus Conventional Radiation Therapy: a Phase II Randomized Controlled Trial.
 Studienleiter:Fr. Dr. med. Evelyn Herrmann


Status: aktiv seit 16.08.2017

 

Ordner-Nr. 2016-00602

  • PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
 Studienleiter:Prof. Dr. Carlo Largiader
 Co-Investigator:Prof. Dr. Daniel Aebersold
 Study-Nurse:Dr. med. Marc Wehrli


Status: aktiv seit 07.09.2017

 

Ordner-Nr. 2016-01487

  • EORTC_31102_TIGER_1407-GUCG: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 08.07.2019

 

Ordner-Nr.

  • EORTC 1811 - E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe EORT: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients
 Studienleiter:Dr.med. Hossein Hemmatazad
 Study-Nurse:Herr Timo Nannen
 Back-up:Frau Brigitte Dorn


Status: aktiv seit 25.10.2019

 

Ordner-Nr. 2020-00804 (Covid-19

  • SAKK 80/20 Covid 19: Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study.
 Studienleiter:Frau Dr.med. Franziska Zenger
 Study-Nurse:Frau Doris Jäggi-Meinken


Status: aktiv seit 16.04.2020

 

Ordner-Nr. 2019-00543

  • Celgene JCART 001_LTFU: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Herr Martin Lange


Status: aktiv seit 23.09.2020

 
zurück nach oben

Blase

Ordner-Nr. 2020-02348

  • SGN22E-003: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
 Studienleiter:Frau Dr.med. Berna Özdemir
 Study-Nurse:Frau Barbara Uhlmann Weber
 Back-up:Frau Nicole Corballis


Status: aktiv seit 10.03.2021

 
zurück nach oben

Hirn

Ordner-Nr.

  • RESURGE: Randomized controlled comperative phase II trial on surgery for glioblastoma recurrence

    Kurzprotokoll
 Studienleiter:PD Dr. med. Philippe Schucht
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Karin Lussi
Hinweis: Diese Studie wird durch die Neurochirurgie durchgeführt.


Status: aktiv seit 18.05.2015

 

Ordner-Nr.

  • IOSI-RTO-001: Stereotactic Radiosurgery or Hypofractionated Image-Guided Radiotherapy to the surgical cavity after resection of brain metastases: a multicenter, single arm, open-label, phase II trial
 Studienleiter:Fr. Dr. med. Evelyn Herrmann
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 04.09.2018

 

Ordner-Nr. 2020-02513

  • CDI-CS-002: An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Bettina Cliffe


Status: aktiv seit 31.03.2021

 

Ordner-Nr. 2018-020002

  • PH-L19TNFGLIO-02-18 : A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF in patients with isocitrate dehydrogenase (IDH) wildtype WHO grade III-IV glioma at first relapse.
 Studienleiter:Frau Dr.med. Franziska Zenger
 Study-Nurse:Frau Nicole Corballis


Status: aktiv seit 19.11.2020

 

Ordner-Nr. 2018-01870

  • Pergola: PEMBROLIZUMAB FOR NEWLY DIAGNOSED GLIOBLASTOMA: A PROSPECTIVE, OPEN-LAB, SINGLEARM, MULTICENTER PHASE II STUDY. PERGOLA
 Studienleiter:Frau Dr.med. Franziska Zenger
 Study-Nurse:Frau Monika Bürki
 Back-up:Frau Nicole Corballis


Status: aktiv seit 11.01.2021

 

Ordner-Nr. 2019-01290

  • INCB 54828-207: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 16.03.2021

 

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2021

 
zurück nach oben

Hoden

Ordner-Nr. 2019-00796

  • SAKK 01/18: Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts
 Studienleiter:Dr.med. Mohamed Shelan
 Co-Investigator:Prof.Dr.med. Jörg Beyer
 Study-Nurse:Frau Sandra Rohner
 Back-up:Frau Nicole Corballis


Status: aktiv seit 19.07.2019

 

Ordner-Nr. PB_2016-00235

  • SAG TCCS: Swiss Austrian German Testicular Cancer Cohort Study
 Studienleiter:Prof.Dr.med. Jörg Beyer


Status: aktiv seit 17.08.2020

 
zurück nach oben

Kolorektal

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2021

 
zurück nach oben

Kopf/Hals

Ordner-Nr. 2016-00733

  • UP-FRONT NECK Trial: Definitive (chemo)-radiotherapy with or without up-front neck dissection for regionally advanced Head and Neck Squamous Cell Carcinoma - A phase III multi-center prospective randomized controlled trial with two additional observational cohort”
 Studienleiter:Dr. med. Olgun Elicin
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.12.2016

 

Ordner-Nr. 2019-00863

  • Proteomics Approach : A single-cell proteomics approach to predict chemoradiation-induced toxicities in patients with advanced head and neck squamous cell carcinoma


Status: aktiv seit 23.01.2020

 

Ordner-Nr. 2019-01506

  • VoiceS: Voice Quality after Transoral CO2-Laser Surgery versus Single Vocal Cord Irradiation for Unilateral Stage 0 & I Glottic Larynx Cancer – A Randomized Phase III Trial
 Studienleiter:Dr. med. Olgun Elicin
 Study-Nurse:Herr Timo Nannen


Status: aktiv seit 15.01.2020

 
zurück nach oben

Leber/Gallengang

Ordner-Nr. 2019-00660

  • INCB 54828-302: A phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of INCB054828 versus Gemcitabine plus chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 31.03.2020

 

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2021

 
zurück nach oben

Leukämien

Ordner-Nr. 2019-01281

  • HOVON 150: A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF IVOSIDENIB OR ENASIDENIB IN COMBINATION WITH INDUCTION THERAPY AND CONSOLIDATION THERAPY FOLLOWED BY MAINTENANCE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES WITH EXCESS BLASTS-2 (MDS-EB2) WITH AN IDH1 OR IDH2 MUTATION, ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Frau Dr.med. Susanne Bürki
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Monika-Krista Zackel


Status: aktiv seit 27.01.2021

 

Ordner-Nr. 2020-00182

  • HOVON 156: A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, STUDY OF GILTERITINIB VERSUS MIDOSTAURIN IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY ONE-YEAR MAINTENANCE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES WITH EXCESS BLASTS-2 (MDS-EB2) WITH FLT3 MUTATIONS ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Monika-Krista Zackel


Status: aktiv seit 27.01.2021

 

Ordner-Nr. 2020-01053

  • HDMM Trial: HDM201 and midostaurin (HDMM) in relapsed/refractory AML with FLT3mut and TP53wt, a phase I study. HDMM IIT
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Herr Martin Lange


Status: aktiv seit 16.11.2020

 
zurück nach oben

Lunge (NSCLC)

Ordner-Nr. 2018-01254

  • SAKK 19/17: First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II. trial.
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 04.03.2020

 

Ordner-Nr. 2018-01756

  • LuCimiR : Circulating biomarkers in lung cancer
 Studienleiter:Dr. med. Simon Häfliger


Status: aktiv seit 26.11.2018

 

Ordner-Nr. 2019-01234

  • ETOP-14-18 CHESS: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic nonsmall cell lung cancer
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 27.04.2020

 

Ordner-Nr. 2019-02378

  • SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Barbara Uhlmann Weber
 Back-up:Frau Nicole Corballis


Status: aktiv seit 06.05.2020

 

Ordner-Nr. 2018-00217

  • CACZ885T2301- CANOPY: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Tanja Mombelli


Status: aktiv seit 26.06.2020

 

Ordner-Nr. 2020-00166

  • GO41717 SKYSCRAPER-01: GO41717: A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE ORMETASTATIC PD-L1- SELECTED NON-SMALL CELL LUNG CANCER.
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 03.07.2020

 

Ordner-Nr. 2020-01839

  • SAKK 17/18: ORIGIN: Overcoming Resistance to Immunotherapy combining Gemcitabine with atezolizumab in advanced NSCLC and mesothelioma progressINg under immune-checkpoint inhibitors or gemcitabine. A multicenter, single-arm, open label phase II trial with two cohorts.
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Yaël Balderer


Status: aktiv seit 25.03.2021

 
zurück nach oben

Lunge (SCLC)

Ordner-Nr. 2019-02067

  • SAKK ACHILES: A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Nicole Corballis


Status: aktiv seit 04.03.2020

 
zurück nach oben

Lymphome: Diverse

Ordner-Nr. 2016-01351

  • BAL-trial: Brentuximab Vedotin and BeEAM high-dose chemotherapy (B-BeEAM) with autologous stem cell transplantation for CD30+ lymphomas, a phase I/II study (the BAL-trial).
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Herr Martin Lange
 Back-up:Frau Anke Klingenberg-Rettich
Hinweis: Start Phase 2: 27.01.2021


Status: aktiv seit 27.01.2021

 

Ordner-Nr. 3473

  • HOVON 127 / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Herr Martin Lange
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 07.05.2018

 

Ordner-Nr. 2017-01223

  • PAMAL trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 20.11.2017

 

Ordner-Nr. 2018-00162

  • Amgen 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 23.09.2020

 

Ordner-Nr. 2018-00828

  • Symptom prevalence and health related quality of life in patients with lymphoma undergoing high-dosage chemotherapy and autologous stem cell transplantation – a longitudinal observation study


Status: aktiv seit 06.07.2018

 

Ordner-Nr. 2019-00582

  • IELSG 47 - MALIBU: Phase II Study of Ibrutinib and Rituximab in untreated Marginal Zone Lymphomas
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Bettina Cliffe
Hinweis: Meldung der SAKK vom 30. Aug. 2020: We would like to inform you that the enrolment of NMZL patients is closed as there are no more slots available (only 15 patients according to the protocol). Therefore, only EMZL can be enrolled in the IELSG47 study. Meldung der SAKK vom 15. Mai 2020: We would like to inform you that the enrolment of SMZL patients is closed as there are no more slots available (only 15 patients according to the protocol). Therefore, only EMZL and NMZL can be enrolled in the IELSG47 study (NMZL up to 15 patients).


Status: aktiv seit 06.05.2020

 

Ordner-Nr. 2020-01973

  • LAB-CAR: CAR-T cell companion diagnostics in patients with B-lymphoproliferative malignancies: digital droplet PCR (ddPCR) versus flow cytometry for CAR-T cell quantification
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel


Status: aktiv seit 01.12.2020

 
zurück nach oben

Lymphome: Hodgkin

  • zur Zeit keine aktive Studie
zurück nach oben

Lymphome: Multiples Myelom

Ordner-Nr. 2018-00615

  • MOCCCA-trial: A randomized phase II trial comparing stem cell mobilization with hemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients.
 Studienleiter:Frau Dr. med. Barbara Jeker
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 20.09.2018

 

Ordner-Nr. 2017-01223

  • PAMAL Trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 21.11.2017

 

Ordner-Nr. 2020-00777

  • Celgene KarMMa-3 / bb2121-MM-003: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Ursula Riesen
 Back-up:Frau Karin Pagalies


Status: aktiv seit 12.04.2021

 
zurück nach oben

Magen

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2021

 
zurück nach oben

Mamma

Ordner-Nr. 2019-01455

  • ERYT/CoordiFit-Study: Eurythmy therapy (ERYT) as a treatment option for fatigue in metastatic breast cancer patients - a randomized, controlled, multi-center trial.
 Studienleiter:Fr. Dr. med. Manuela Rabaglio


Status: aktiv seit 08.06.2020

 
zurück nach oben
"Prevention (Postmenopausal)"
  • zur Zeit keine aktive Studie
zurück nach oben
"Early"

Ordner-Nr.

  • CAPRICE study: Importance of exercise training therapy timing with regard to cardiotoxicity and patient preference in early breast cancer patients undergoing adjuvant chemo-therapy
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
Hinweis: Die Studie wird in Zusammenarbeit mit der Prof. Dr. med. M. Wilhelm, Präventive Kardiologie und Sportmedizin durchgeführt.


Status: aktiv seit 08.06.2020

 

Ordner-Nr. 2019-00686

  • IBCSG 59-19 / BIG 18-02 POLAR: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Monika Bürki
 Back-up:Frau Olivia Aerni


Status: aktiv seit 27.04.2020

 

Ordner-Nr. 2018-01210

  • IBCSG 55-17 TOUCH: Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Monika Bürki


Status: aktiv seit 23.09.2020

 
zurück nach oben
"Lokalrezidiv"
  • zur Zeit keine aktive Studie
zurück nach oben
"Advanced"
  • zur Zeit keine aktive Studie
zurück nach oben
"Male"
  • zur Zeit keine aktive Studie
zurück nach oben

Melanom

  • zur Zeit keine aktive Studie
zurück nach oben

Mesotheliom

  • zur Zeit keine aktive Studie
zurück nach oben

Neuroendokrine Tumoren

Ordner-Nr. 2017-00466

  • COMPETE: A prospective, randomised, Controlled, Open-Label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 1 77Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptorpositive (SSTR+) , neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). COMPETE. ITM - LET - 01.
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 27.12.2017

 
zurück nach oben

Oesophagus

Ordner-Nr. 2020-01826

  • YO42137: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Yaël Balderer


Status: aktiv seit 02.12.2020

 
zurück nach oben

Ovar, Cervix, Endometrium

Ordner-Nr. 2020-00148

  • MATAO: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)
 Studienleiter:Frau Dr.med. Franziska Zenger
 Study-Nurse:Frau Olivia Aerni


Status: aktiv seit 08.03.2021

 
zurück nach oben

Pankreas

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 25.03.2021

 
zurück nach oben

Prostata

Ordner-Nr. 2017-00842

  • EORTC Radiation Oncology Group EORTC Genito-Urinary Cancers Group (EORTC 1414-RO: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus)
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Frau Ulla Schüpbach


Status: aktiv seit 29.01.2018

 

Ordner-Nr. 2018-00164

  • STORM: Salvage treatment of oligo recurrent nodal prostate cancer metastases. To compare metastases-free survival between metastasis-directed therapy and metastasis-directed therapy with whole pelvis RT
 Studienleiter:Dr.med. Mohamed Shelan
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Herr Timo Nannen


Status: aktiv seit 24.01.2019

 
zurück nach oben

Sarkome

Ordner-Nr. 2017-01063

  • E-trab: GERIATRIC ASSESSMENT OF ELDERLY “UNSUITED” PATIENTS RECEIVING TRABECTEDIN IN FIRST LINE TREATMENT FOR ADVANCED SOFT TISSUE SARCOMAS (STS)
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Nicole Corballis


Status: aktiv seit 25.10.2017

 
zurück nach oben

Solide Tumoren

Ordner-Nr. 2019-01290

  • INCB 54828-207: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEMIGATINIB IN PARTICIPANTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED/METASTATIC OR SURGICALLY UNRESECTABLE SOLID TUMOR MALIGNANCIES HARBORING ACTIVATING FGFR MUTATIONS OR TRANSLOCATIONS
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 09.06.2020

 

Ordner-Nr. 2020-02311

  • Merck 7902-005 Basket: Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Tanja Mombelli
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2021

 
zurück nach oben

Supportivtherapie

  • zur Zeit keine aktive Studie
zurück nach oben

Urothelkarzinom/Nierenzellkarzinom

Ordner-Nr.

  • IPSEN F-FR-60000-023 : A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
 Studienleiter:Frau Dr.med. Berna Özdemir
 Study-Nurse:Frau Barbara Uhlmann Weber
 Back-up:Frau Nicole Corballis


Status: aktiv seit 26.10.2020

 
zurück nach oben